1 s e p t e m b e r 2 0 1 6 | V O L 5 3 7 | N A t U r e | 6 3 ArticLe Hypermethylation of the promoters of tumour suppressor genes represses transcription of these genes, conferring growth advantages to cancer cells. How these changes arise is poorly understood. Here we show that the activity of oxygendependent teneleven translocation (TET) enzymes is reduced by tumour hypoxia in human and mouse cells. TET enzymes catalyse DNA demethylation through 5methylcytosine oxidation. This reduction in activity occurs independently of hypoxiaassociated alterations in TET expression, proliferation, metabolism, hypoxiainducible factor activity or reactive oxygen species, and depends directly on oxygen shortage. Hypoxiainduced loss of TET activity increases hypermethylation at gene promoters in vitro. In patients, tumour suppressor gene promoters are markedly more methylated in hypoxic tumour tissue, independent of proliferation, stromal cell infiltration and tumour characteristics. Our data suggest that up to half of hypermethylation events are due to hypoxia, with these events conferring a selective advantage. Accordingly, increased hypoxia in mouse breast tumours increases hypermethylation, while restoration of tumour oxygenation abrogates this effect. Tumour hypoxia therefore acts as a novel regulator of DNA methylation.
Although the mutagenic processes underlying oncogenesis are well studied, tumours are known to be not only genetically but also epigenetically distinct from their tissue of origin. The most extensively documented examples of oncogenic epigenetic changes are those to DNA methylation, but the underlying mechanisms are poorly understood 1 .
In tumours, changes in DNA methylation involve both global hypomethylation and the local hypermethylation of CpG-rich gene promoters 1 . Hypermethylation frequently affects tumour suppressor genes (TSGs), downregulating their expression and thus contributing to oncogenesis. It remains unclear how methylation changes arise, but an instructive model suggests that genetic changes are a prerequisite for methylation changes 2 ; BRAF mutations, for instance, lead to hypermethylation in colorectal tumours 3 . This is problematic as, while pervasive, hypermethylation of TSGs can only be explained by somatic mutations in a fraction of tumours. Notably, extensive hypermethylation can be seen in ependymomas completely devoid of somatic mutations 4 .
In contrast to DNA methylation mechanisms, those of demethylation have remained elusive until recently, when TET methylcytosine dioxygenases (TET1, TET2 and TET3) were shown to oxidize 5-methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC) 5 . 5-Hydroxymethylcytosine and its further-oxidized derivatives are subsequently replaced with an unmodified cytosine by base-excision repair to achieve demethylation 6 . Reduced 5mC oxidation due to decreased TET activity thus increases levels of DNA methylation. Mutations suppressing TET activity are often found in myeloid leukaemia and glioblastoma [6] [7] [8] [9] , but less frequently in other cancer types. By contrast, 5hmC loss is pervasive in tumours and even proposed as a cancer hallmark 10 . As with hypermethylation, somatic mutations explain the loss of 5hmC in only a fraction of tumours and it remains unclear which other factors trigger this loss 2 .
Notably, like hypoxia-inducible factor (HIF)-prolyl-hydroxylase domain proteins (PHDs), TET enzymes are Fe 2+ -and α-ketoglutaratedependent dioxygenases 11 . PHDs are oxygen-sensitive, acting as oxygen sensors. Under normoxic conditions, they hydroxylate the HIF transcription factors, targeting them for proteasomal degradation, whereas under hypoxia they do not, leading to HIF stabilization and hypoxia response activation 12 . Expanding tumours continuously become disconnected from their vascular supply, resulting in vicious cycles of hypoxia, HIF activation and tumour vessel formation 13 . Consequently, hypoxia pervades in solid tumours. Oxygen levels range from 5% to anoxia and around one-third of tumour areas contain less than 0.5% oxygen 14 . Although DNA hypermethylation and hypoxia are well-recognized cancer hallmarks, the effect of hypoxia on TET hydroxylase activity and subsequent DNA de-methylation has not been assessed. We therefore set out to investigate whether a hypoxic micro-environment decreases TET hydroxylase activity in tumours, leading to an accumulation of 5mC and acquisition of hypermethylation.
Effect of hypoxia on DNA hydroxymethylation
To assess whether hypoxia affects TET activity, we exposed ten human and five murine cell lines with detectable 5hmC levels to 21% O 2 (normoxic) or 0.5% O 2 (hypoxic, commonly observed in tumours 14 ) for 24 h. Hypoxia induction was verified and DNA was extracted and profiled for nucleotide composition using liquid chromatographymass spectrometry (LC-MS). We observed 5hmC loss in eleven cell lines, including eight cancer cell lines (Fig. 1a ). However, this did not translate into global 5mC increases (Extended Data Fig. 1 ), presumably because 5mC is more abundant and is not targeted by TETs at many sites 15 . The effect of hypoxia was concentration-and time-dependent: a dose-response revealed loss of 5hmC at oxygen levels at-or-below 2%, and a 20% and 40% reduction, respectively, after 15 h and >24 h of hypoxia (Fig. 1b, c) . Loss of 5hmC was not due to increased 5hmC oxidation to 5fC 16 , as hypoxia also decreased 5fC levels in embryonic stem (ES) cells (Extended Data Fig. 1 ).
In some cell lines, levels of 5hmC failed to decrease under hypoxia. 5hmC levels were unaffected in cell lines H1299 and 4T1, and even increased in SHSY5Y and SK-N-Be2c neuroblastoma cells, as reported previously 17 (Fig. 1a ). When profiling TET expression, neuroblastoma cells displayed potent hypoxia-dependent induction of TET1 and TET2. Cell lines H1299 and 4T1 exhibited intermediate increases in expression levels, whereas all other cell lines showed no, or modest, increases of some TET paralogues (Fig. 1a ). Tet gene expression changes were confirmed at the protein level in mouse cell lines, and HIF1β-chromatin immune precipitation followed by sequencing (ChIP-seq) further confirmed that HIF binds near the promoters of upregulated Tet genes, but not near those that are unaltered (Extended Data Fig. 2a, b ), in keeping with the cell-type specificity of the hypoxia response 12 . Notably, no cell line showed decreased Tet expression, indicating that 5hmC loss is not due to reduced Tet expression.
Since hypoxia affects TET paralogue expression differently in different cell lines we correlated hypoxia-associated changes in overall TET expression (the combined abundances of TET1, TET2 and TET3) with changes in 5hmC levels. Hypoxia reduced 5hmC levels by an average of 44% (P = 0.0097) in each cell line ( Fig. 1d ), independently of TET expression changes. Nevertheless, changes in TET expression also affected 5hmC levels. This was confirmed by short interfering RNA (siRNA) knockdown of TET2, which constitutes around 60% of all TET expression in MCF7 cells. This reduced 5hmC levels by around 60% (Extended Data Fig. 2c ). Similarly, Tet1 knockout mouse ES cells (Tet1 −/− ) displayed lower 5hmC levels than wild-type ES cells, in which Tet1 is the predominantly expressed Tet paralogue under both normoxic and hypoxic conditions ( Fig. 1a, Extended Data Fig. 2d ).
Post-hypoxic 5hmC levels therefore appear to be determined by altered oxygen availability and by changes in TET abundance. This explains why cell lines that do not upregulate TET expression in response to hypoxia display 5hmC loss, whereas cell lines that strongly RNA expression is expressed relative to the combined estimated level of all 3 TET paralogues under 21% O 2 . b, c, 5hmC/C levels in MCF7 cells exposed to different O 2 levels for 24 h (b), or 0.5% O 2 for indicated times (c). d, Correlation of changes in overall TET expression and 5hmC upon hypoxia. Each circle represents a cell line, the full line the correlation. e, f, Levels of 5hmC (e) and α-ketoglutarate (αKG) (f) in MCF7 cells grown with ascorbate (e), water or dimethyl-α-ketoglutarate (2me-αKG) (f) under 21% (white) or 0.5% (red) O 2 . α-ketoglutarate changes are relative to matching water controls. g, As in a, but for cells exposed to IOX2. h, i, Michaelis-Menten curve of Tet1 (h) and Tet2 (i, n = 3) for O 2 . K m denotes Michaelis constant. Error bars denote s.e.m., grey areas: 95% confidence interval, n = 5 replicates for a-h, *P < 0.05, **P < 0.01, ***P < 0.001 by t-test (b, c, e) or analysis of variance (ANOVA) with post-hoc Tukey HSD test (f). upregulate TET compensate for this, resulting in equal or increased 5hmC levels.
Hypoxia directly affects DNA hydroxymethylation
Aside from gene expression, TET activity is affected by a variety of cellular processes, including changes in levels of reactive oxygen species (ROS), Krebs cycle metabolites and proliferation 7, 11, 17, 18 . Since such changes might also occur secondary to hypoxia, we investigated whether they underlie 5hmC reductions in hypoxia.
First, we assessed whether ROS could affect TETs in the nucleus through inactivation of Fe 2+ in their catalytic domain. Although hypoxia increased overall ROS levels, no increase in nuclear ROS was detected either by a nucleus-specific ROS probe or through 8-oxoguanine (8-oxoG) quantification (Extended Data Fig. 3a-f ). Moreover, ascorbate supplementation to counteract ROS increases 19 failed to rescue 5hmC loss ( Fig. 1e ).
Second, because changes in metabolites such as succinate and fumarate compete with TET for its cofactor α-ketoglutarate 7 , we investigated whether this was relevant. The concentration of these metabolites, however, was not increased in hypoxic MCF10A or embryonic stem (ES) cells, and only 3-4-fold in MCF7 cells (Extended Data Fig. 3g -i). Levels of the onco-metabolite 2-hydroxyglutarate were also increased in hypoxic MCF7 and MCF10A cells, but were still only around 5-10% of αKG (Extended Data Fig. 3h , j), and therefore unlikely to affect TET activity, as affinity of these competing metabolites for hydroxylases is lower or similar to αKG 7,20 . Culturing MCF7 cells in glutamine-free medium to decrease the concentration of these metabolites did not alter 5hmC levels (Extended Data Fig. 3k ). Similarly, exogenous addition of cell-permeable αKG under hypoxia to counteract putative competing metabolites did not rescue the 5hmC loss ( Fig. 1f ). This therefore precluded metabolite competition from causing hypoxia-associated 5hmC loss.
Third, increases in cell proliferation have also been linked to 5hmC loss 21 . However, cell growth was unaffected or decreased upon exposure to hypoxia in all cell lines tested, indicating that increased proliferation does not underlie 5hmC reduction (Extended Data Fig. 3l ).
Fourth, to exclude any potential cellular changes caused by HIF activation, we pharmacologically activated the hypoxia response program by exposing five cell lines grown in atmospheric conditions to IOX2, a small molecule inhibitor with high specificity for PHDs 22 (Extended Data Fig. 3m ). Cell lines not characterized by hypoxia-induced TETexpression changes (MCF10A, A549 and MCF7) showed no change in 5hmC levels under IOX2, while those characterized by TET upregulation (SK-N-Be2c and SHSY5Y) showed an increase in 5hmC ( Fig. 1g ). Thus, after IOX2 exposure, changes in 5hmC levels mirrored changes in TET transcription. We also prepared nuclear protein extracts from MCF7 cells grown under hypoxic and atmospheric conditions, and then compared their 5mC oxidative capacities at the same oxygen tension in vitro. These, however, were identical (Extended Data Fig. 3n ). Loss of 5hmC was therefore not due to activation of the hypoxia response program.
Finally, we assessed the effect of varying oxygen concentrations on the activity of recombinant purified Tet1 or Tet2, by measuring conversion of 5mC to 5hmC on double-stranded genomic DNA. We observed a dose-dependent reduction in 5hmC production with decreasing concentrations. Importantly, under the hypoxic conditions applied in this study (0.5% O 2 ), Tet1 and Tet2 activity were reduced by 45% ± 7 and 52% ± 8 (mean ± s.e.m., P = 0.01; Fig. 1h , i).
Together, these data demonstrate that decreased oxygen availability directly diminishes the oxidative activity of TETs, independently of changes in HIF activity, competing metabolites, proliferation, nuclear ROS or TET expression.
Loci with differential DNA hydroxymethylation
To analyse where in the genome hypoxia reduces 5hmC. DNA from hypoxic and normoxic MCF7 cells was immunoprecipitated using antibodies targeting 5mC or 5hmC and subjected to high-throughput sequencing (DIP-seq). We detected 290,382 sites enriched for 5hmC. After hypoxia, 10,001 of the peaks generated for each site exhibited a decrease in 5hmC (5% false discovery rate (FDR)) and only 18 exhibited an increase, thereby confirming global 5hmC loss ( Fig. 2a , Supplementary Table 1 ). Genomic annotation of these peaks using chromHMM 23 revealed they were predominantly found at gene promoters, with some at enhancers and actively transcribed regions, in line with known TET-binding sites 15 (Fig. 2b ). For example, 5hmC was decreased near transcription start sites of TSGs NSD1, FOXA1 and CDKN2A (Extended Data Fig. 4 ). Analysis of 5mC-DIP signals at these 10,001 regions highlighted that, in 724 out of 875 altered regions, the 5mC content was significantly increased (P < 0.05), although only one of these sites survived a 5% FDR correction ( Fig. 2c , Supplementary  Table 2 ). Increases in 5mC were thus more subtle than decreases observed for 5hmC.
Several days may be required for 5hmC changes to translate into 5mC changes 19 . We therefore cultured cells for 48 h (rather than 24 h) under hypoxia, and used targeted bisulfite-sequencing (BS-seq) to obtain base-resolution quantitation of 5mC at around 85 Mb of promoters and enhancers. Using this approach, we could assess increases in 5mC for 1,894 of the 10,001 regions displaying 5hmC loss. As observed after 5mC-DIP-seq, 301 out of 402 altered sites displayed increased methylation (P < 0.05). Similarly, 60 out of 99 altered sites were increased with 5% FDR correction (P = 2.8 × 10 −3 ; Fig. 2d , Supplementary  Table 3 ). ChromHMM annotation revealed that these 60 sites were predominantly in gene promoters and enhancers. To assess the effect of hypermethylation on gene expression, we performed RNA sequencing (RNA-seq) on hypoxic MCF7 cells. Genes depleted in 5hmC and with increased 5mC showed significantly decreased expression upon hypoxia ( Fig. 2e ; P = 2.5 × 10 −42 and 7.4 × 10 −4 , respectively, for 3,660 Article reSeArcH genes with 5hmC loss and 55 genes with both 5hmC loss and 5mC gain; Supplementary Table 4 ). Reduced TET activity therefore leads to an accumulation of 5mC, decreasing the expression of associated genes.
Hypermethylation events in hypoxic tumours
We next assessed whether 5hmC loss and concomitant 5mC gain also occur in vivo. We focused on gene promoters as they are more frequently affected upon hypoxia, and directly linked to gene expression. As cancer cells go through multiple rounds of sustained hypoxia 14 , we proposed that there would be an increase in 5mC, as it would provide a selective advantage for cancer cells, similar to somatic mutations. We therefore assessed 5hmC levels in three patient-derived tumour xenografts, in which we marked hypoxic areas with pimonidazole (Extended Data Fig. 5a ). Immunofluorescence analysis revealed decreased 5hmC in hypoxic areas, linking tumour hypoxia to 5hmC loss in vivo.
To assess whether hypoxia-associated hypermethylation contributes to the oncogenic process, we analysed tumours profiled in the pan-cancer study of The Cancer Genome Atlas (TCGA) 24 . We selected 8 solid tumour types (3,141 tumours) for which both DNA methylation (450k array) and gene expression (RNA-seq) data were available for >100 samples, and classified each as hypoxic, normoxic or intermediate using an established gene signature 25 (Extended Data Fig. 5b ). Next, we analysed tumour-associated DNA hypermethylation in each tumour type by performing unsupervised clustering of 1,000 CpGs that displayed the strongest hypermethylation in tumour versus normal tissue (Extended Data Fig. 5c ). In the first three clusters (displaying low, intermediate and high average hypermethylation), we analysed the enrichment of hypoxic tumours. For all eight tumour types, hypoxic tumours predominated in the hypermethylated cluster and normoxic tumours in the hypomethylated cluster ( Fig. 3a ; P = 2 × 10 −4 ), suggesting that hypoxia leads to increased methylation in tumours.
Whereas the prior analysis identified uniform increases in methylation based on average changes, it poorly captured exceptional increases in hypermethylation known to occur in a subset of tumours 1, 26 . We therefore also modelled tumour hypermethylation by annotating increases in CpG methylation at gene promoters using a stringent threshold (Bonferroni-corrected P < 0.05) as hypermethylation events. In each tumour type, the promoters of 187 ± 38 out of 29,649 genes frequently displayed hypermethylation events ( Supplementary Table 5 ).
Notably, hypoxic tumours had on average 4.8-fold more hypermethylation events in these genes than normoxic tumours ( Fig. 3b ; P = 4.1 × 10 −13 ). These events were functional, reducing gene expression in tumours carrying these hypermethylation events (Extended Data Fig. 5d ). They primarily affected promoters with high or intermediate CpG content, in line with TET target preference (Extended Data Fig. 5e ) 15 . Furthermore, they were not restricted to a small subset: 77% ± 6.5, 49% ± 9.3 or 39% ± 9.1 of hypoxic tumours were affected by ≥1, ≥10 or ≥20 hypermethylation events, respectively. Considering hypermethylation frequency in normoxic tumours as baseline, up to 48% of hypermethylation events were hypoxia-related.
As hypermethylation can also be genetically encoded, mutations in some genes correlated positively with hypermethylation (for example, IDH1, TET1, TET3 and BRAF; Supplementary Table 6 ). Importantly, hypoxia predicted hypermethylation independent of mutation status (P = 6.1 × 10 −12 ). Mutations inhibiting TET activity were infrequent (approximately 1.8% of tumours), indicating that hypermethylation is not genetically encoded in most tumours. TET-mutant tumours were also not more hypoxic, suggesting that hypoxia induces hypermethylation, and not vice versa (Extended Data Fig. 5f ). Hypoxia-associated hypermethylation events occurred independently of other tumour characteristics such as tumour cell percentage, immune cell infiltration, tumour size, proliferation or metastasis (P = 4 × 10 −13 ), and were significant in seven out of eight tumour types ( Supplementary Tables 7, 8 ).
In line with an earlier report 21 , high proliferation was the only other variable significantly predicting hypermethylation (P = 5.3 × 10 −10 ), although only in four of eight tumour types (Extended Data Fig. 5g , h). Using multiple regression, we estimated the contribution of tumour characteristics to hypermethylation variance. On the basis of partial correlation coefficients, proliferation predicted 12.1% ± 4.1, and hypoxia 33.3% ± 5.7, of hypermethylation events explained by the model (Extended Data Fig. 5i ).
Given the increase in hypermethylation events in hypoxic tumours, we next selected genes with more hypermethylation events in hypoxic versus normoxic tumours (5% FDR). This revealed 263 ± 94 genes per tumour type, with 9.0% ± 1.6 being shared between any two types (Supplementary Table 9 ). Ontology analysis of hypermethylated genes revealed that they had biological processes in common such as cell cycle arrest, DNA repair and apoptosis. Hypermethylation was also observed in genes involved in suppressing glycolysis, angiogenesis and metastasis, consistent with tumour hypoxia inducing these processes (Extended Data Fig. 6a -c).
Reduced TET activity underlies hypermethylation
We used three strategies to confirm the role of TET activity in hypoxiaassociated hypermethylation. First, we correlated TET expression with hypermethylation events, correcting for hypoxia and proliferation. TET2 and TET3 expression inversely correlated with hypermethylation (P = 0.046 and 0.0028, Extended Data Fig. 7a ), as did hypoxia and proliferation (P < 1.2 × 10 −13 for both). Similar to our in vitro observations, this implicates reduced TET activity in hypermethylation.
Second, we assessed the overlap of hypermethylation events induced by hypoxia and IDH1 R132 mutations 8 in 63 glioblastomas. Among wild-type IDH1 glioblastomas, hypermethylation frequency was 3.4fold higher in hypoxic tumours ( Fig. 4a , Extended Data Fig. 7b ). As expected, IDH1 R132 tumours were hypermethylated, albeit 3.9-fold more so than hypoxic tumours (Fig. 4a ). This indicates that TET enzymes, fully inactivated in IDH-mutant tumours 9 , were only partially inactivated in hypoxia, similar to our in vitro observations. Of 228 genes frequently hypermethylated in glioblastomas, those in the hypoxic and IDH-mutant subgroups displayed a 58% overlap (P < 10 −16 ; Fig. 4b ) and reduced expression (Extended Data Fig. 7c ), indicating that loss of TET activity affects the same genes, regardless of the underlying trigger.
Finally, to link hypoxia-associated hypermethylation to 5hmC loss, we profiled 24 non-small-cell lung tumours for 5mC and 5hmC using 450k arrays (Extended Data Fig. 7d ). This revealed a generalized loss of 5hmC in hypoxic tumours (−7.1% ± 1.1; P = 3.7 × 10 −3 ; Fig. 4c ). Individual probes also mostly displayed 5hmC loss and 5mC gain in hypoxic tumours (96.7% and 65.4% of probes altered, respectively, P < 0.01; Supplementary Table 10 ). Of all probes displaying 5mC gain, most (87%) also displayed 5hmC loss, and of probes altered both in 5hmC and 5mC (P < 0.01), 92% showed 5hmC loss and 5mC gain ( Fig. 4d ; P < 10 −16 ). This directly implicates hypoxia-induced loss of 5hmC in the hypermethylation of hypoxic tumours.
Rescue of hypoxiainduced hypermethylation
To manipulate tumour oxygenation and confirm its effect on hypermethylation, we used mice expressing the polyomavirus middle T-antigen under the mouse mammary tumour virus promoter (MMTV-PyMT). These mice spontaneously develop breast tumours, with hypoxic areas emerging from 7 weeks onwards, encompassing approximately 20% of the tumour at 16 weeks 27 . Hypoxic areas in these tumours were also depleted in 5hmC ( Fig. 5a, b ). We monitored hypermethylation changes by targeted BS-seq of TSG promoters commonly inactivated in cancer 28 . Hypoxic human breast tumours displayed a specific increase in hypermethylation at these TSG promoters, whereas no effect was observed for oncogenes (Extended Data Fig. 8a ). In line with the age-associated increase in tumour hypoxia 27 , hypermethylation events also increased markedly with age (and tumour size), but not in normal mammary glands (Extended Data Fig. 8b-d ). Importantly, >95% of cells in these tumours were PyMT-positive, whereas cell proliferation and immune cell infiltration were comparable between hypoxic and normoxic areas (Extended Data Fig. 8e -g). Hypermethylation changes are therefore unlikely to be a result of changes in proliferation or cellular heterogeneity.
To test whether reduced tumour oxygenation increases hypermethylation, 9-week-old MMTV-PyMT mice were hydrodynamically injected with a soluble-Flk1 (sFlk1)-expressing plasmid. After 3 weeks, this caused tumour vessel pruning and hypoxia (Extended Data Fig. 9a-d ). Shallow whole-genome sequencing for 5hmC (TET-assisted bisulfite sequencing; TAB-seq) revealed a global loss of 5hmC after sFlk1 overexpression (−12.4% ± 3.5, P = 0.040), occurring predominantly at gene-dense regions and affecting the entire gene ( Fig. 5c , Extended Data Fig. 9e ), consistent with previously described 5hmC distributions 15 . Moreover, targeted BS-seq revealed an exacerbated hypermethylation phenotype after sFlk1 overexpression at 12 weeks in TSGs but not oncogenes (10 out of 15 TSGs contained ≥1 hypermethylation event; P = 0.010, Fig. 5d , Extended Data Fig. 9f ). Tumour growth and the expression of proliferation markers, Tet paralogues and the immune cell marker CD45 were unaffected by sFlk1 overexpression, indicating that hypermethylation occurs independently (Extended Data Fig. 9g -j).
To rescue this effect, we normalized the tumour vasculature by intercrossing a heterozygous Phd2 (also known as Egln1) loss-offunction allele with the PyMT transgene. This significantly reduced tumour hypoxia at 16 weeks 27 (Extended Data Fig. 9k ). TAB-seq revealed a 5hmC gain (+25.3% ± 4.7, P = 0.0098) occurring primarily at gene-dense regions and affecting the entire gene ( Fig. 5c , Extended Data Fig. 9l ). Notably, BS-seq revealed that, although 8 out of 15 TSGs displayed ≥1 hypermethylation event in Phd2 +/+ tumours, no hypermethylation was observed in Phd2 +/− tumours (P = 2.6 × 10 −7 , Fig. 5e ). Again, oncogenes were unaffected (Extended Data Fig. 9m ). Effects were independent of Phd2 haplodeficiency in tumour cells, as similar effects were observed in PyMT mice having endothelial-cell-specific Phd2 haplodeficiency 27 (Extended Data Fig. 9n , o). As in the sFlk1 Article reSeArcH model, increasing tumour oxygenation by Phd2 haplodeficiency did not affect tumour growth or the expression of proliferation markers, Tet paralogues or CD45 (Extended Data Fig. 9p -u).
Discussion
We show here that tumour hypoxia directly reduces TET activity, causing a 5hmC decrease predominantly at gene promoters and enhancers. Concomitantly, 5mC increases at these sites and, as with certain genetic mutations, provides a substrate for oncogenic selection in vivo 26 . Since hypoxia prevails in tumours, 5mC changes in TSG promoters are frequent, rendering hypoxic tumours hypermethylated at these sites. Hypermethylation events in tumours have long been suspected to occur through selection of random DNA methylation variants 29 . However, the identification of genetically encoded hypermethylation challenged this stochastic model 2 . By demonstrating that hypoxia drives hypermethylation, we show that genetically-encoded and tumour-microenvironment-driven models of epimutagenesis co-exist. However, since hypoxia is pervasive, the mechanism described here is relevant for most solid tumours. We found that up to 48% of hypermethylation events were hypoxia-related and effects were replicated in all tumour types investigated, independent of mutation-and proliferationinduced hypermethylation. Modest hypoxia (2-5% O 2 ) did not affect TET activity, indicating that TET enzymes are not physiological oxygen sensors (unlike PHDs) in line with previous reports 30 . TET activity only becomes limiting under the pathophysiological oxygen concentrations found in tumours 14 . Analogous to somatic TET haploinsufficiency, this partial reduction in TET activity contributes to oncogenesis. Our findings also suggest intriguing avenues of investigation into other ischaemia-related pathologies.
Our model provides a mechanism for the association between hypoxia and maladaptive oncogenic processes. Genes affected by hypermethylation were not only involved in cell-cycle arrest, DNA repair and apoptosis, but also glycolysis, metastasis and angiogenesis. High doses of angiogenesis inhibitors stimulate metastatic spreading in mouse cancer models (at least in specific settings) 31 , and tumour hypoxia is considered a driver of this behaviour. The mechanism by which hypermethylation accumulates under hypoxia may underlie these escape mechanisms. By contrast, low levels of angiogenic inhibition can induce tumour vessel normalization, and improve oxygenation 32 . Our observations in normalized PyMT tumours suggest that the therapeutic benefits of vessel normalization such as decreased metastatic burden 27 , might occur by inhibiting hypoxia-associated hypermethylation. Countering hypermethylation by inhibiting DNA methylation or by normalizing tumour blood supply may therefore prove to be therapeutically beneficial.
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Materials. All materials were molecular biology grade. Unless noted otherwise, all were from Sigma. Analysis of global 5mC and 5hmC levels in cultured cells. MCF7, MCF10A, A549, H1299, SHSY5Y, Hep G2, Hep 3B2, HT-1080, NCI-H358, LLC, Neuro-2a, 4T1 and SK-N-Be2c cell lines were obtained from the American Type Culture Collection and their identity was not further authenticated. These cell lines are not listed in the database of commonly misidentified cell lines maintained by ICLAC. LLC, Neuro-2a, 4T1, Hep G2, HT-1080, Hep 3B2, MCF7 and A549 cells were cultured at 37 °C in DMEM with 10% fetal bovine serum (FBS), 5 ml of 100 U ml −1 penicillin-streptomycin (Life Technologies) and 5 ml of l-glutamine 200 mM. NCI-H358, H1299 and SK-N-Be2c cell lines were cultured at 37 °C in RPMI 1640 Medium with 10% FBS 1% penicillin-streptomycin and 1% L-glutamine. MCF10A cells were cultured at 37 °C in DMEM/F-12 supplemented with 5% horse serum (Life Technologies), 20 ng ml −1 human epidermal growth factor (Prepotec), 0.5 μg ml −1 hydrocortisone, 100 ng ml −1 cholera toxin, 10 μg ml −1 insulin, and 100 U ml −1 penicillin-streptomycin. The SHSY5Y cell line was cultured at 37 °C in DMEM/F-12 supplemented with 10% FBS, 2% penicillin-streptomycin and 1% non-essential amino acids (MEM). Mouse J1 ES cells were cultured feeder-free in fibroblast-conditioned medium. Cell cultures were confirmed to be mycoplasmafree every month. Cell line treatment conditions. Control cell cultures were grown at atmospheric oxygen concentrations (21%) with 5% CO 2 . To render cultures hypoxic, they were incubated in an atmosphere of 0.5% O 2 , 5% CO 2 and 94.5% N 2 . Where indicated, IOX2 (50 μM), ascorbate (0.5 mM, a dose known to support TET activity 19 ) or dimethyl-α-ketoglutarate (0.5 mM) was added to fresh culture medium, using an equal volume of the carrier (DMSO) as a control for IOX2. Cells were plated at a density tailored to reach 80-95% confluence at the end of the treatment. Fresh medium was added to the cells just before hypoxia exposure. For glutamine-free culture experiments, dialysed FBS was added to glutamine-free DMEM, and supplemented with glutamine (4 mM) for the control. Mouse J1 ES cells and Tet1-gene-trap ES cells were cultured feeder-free in fibroblast-conditioned medium. DNA extraction. After exposure to the aforementioned stimuli, cultured cells were washed on ice with ice-cold PBS with deferoxamin (PBS-DFO, 200 μM), detached using cell scrapers and collected by centrifugation (400g, 4 °C). Nucleic acids were subsequently extracted using the Wizard Genomic DNA Purification kit (Promega) according to instructions. All buffers were supplemented with DFO (200 μM) and DNA was dissolved in 80 μl PBS-DFO with RNase A (200 U, NEB) and incubated for 10 min at 37 °C. After proteinase K addition (200 units) and incubation for 30 min at 56 °C, DNA was purified using the QIAQuick blood and tissue kit (all buffers supplemented with DFO). It was eluted in 100 μl of a 10 mM Tris, 1 mM EDTA solution (pH 8) and stored at −8 °C until further processing. LC-ESI-MS/MS of DNA to measure 5mC, 5hmC and 8-oxoG levels. To measure the cytosine, 5mC, 5hmC and 8-oxoG content of the DNA samples, three technical replicates were run for each sample. More specifically, 0.5-2 μg DNA in 25 μl H 2 O were digested in an aqueous solution (7.5 μl) of 480 μM ZnSO 4 , containing 42 U nuclease S1, 5 U Antarctic phosphatase, and specific amounts of labelled internal standards were added and the mixture was incubated at 37 °C for 3 h in a Thermomixer comfort (Eppendorf). After addition of 7.5 μl of 520 μM [Na] 2 -EDTA solution containing 0.2 U snake venom phosphodiesterase I, the sample was incubated for another 3 h at 37 °C. The total volume was 40 μl. The sample was then kept at −20 °C until the day of analysis. Samples were then filtered by using an AcroPrep Advance 96-filter plate 0.2 μm Supor (Pall Life Sciences) and then analysed by liquid chromatography electrospray ionization tandem mass spectrometry (LC-ESI-MS/MS), which are performed using an Agilent 1290 UHPLC system and an Agilent 6490 triple quadrupole mass spectrometer coupled with the stable isotope dilution technique. DNA samples were digested to give a nucleoside mixture and spiked with specific amounts of the corresponding isotopically labelled standards before LC-MS/MS analysis. The nucleosides were analysed in the positive ion selected reaction monitoring mode (SRM). In the positive ion mode, [M + H] + species were measured. Determination and comparison of nucleoside concentrations. The resulting cytosine, 5mC, 5hmC and 8-oxoG peak areas were normalized using the isotopically labelled standards, and expressed relative to the total cytosine content (that is, C + 5mC + 5hmC). Concentrations were depicted as averages of independent replicates grown on different days, and compared between hypoxia and normoxia (21% O 2 ), or between control and treated conditions, using a paired Student's t-test. No statistical methods were used to predetermine sample size. RNA extraction, cDNA synthesis and qPCR. For RNA extraction, cell culture medium was removed, TRIzol (Life Technologies) added and processed according to manufacturer's guidelines. Reverse transcription and qPCR were performed using 2 × TaqMan Fast Universal PCR Master Mix (Life Technologies), TaqMan probes and primers (IDT, sequence in Supplementary Table 12 ). Thermal cycling and fluorescence detection were done using a LightCycler 480 Real-Time PCR System (Roche). Taqman assay amplification efficiencies were verified using serial cDNA dilutions, and estimated to be >95%. mRNA concentration analysis and statistics. Cycle threshold (C t ) values were determined for each sample and gene of interest in technical duplicates, and normalized according to the corresponding amplification efficiency. Per sample, TET expression was expressed relative to β-2-microglobulin (human) or hypoxanthine phosphoribosyltransferase 1 (Hprt mouse) levels by subtraction of their average C t values. Concentrations were expressed as averages of at least 5 replicates extracted on different days. For Fig. 1a , copy number estimates for TET1, TET2 and TET3 were expressed for each cell line, relative to the summed copy number estimates of TET1, TET2 and TET3 under control conditions (21% O 2 ). Concentrations were compared between hypoxia and normoxia, or between control and treatment conditions using a Student's t-test. No statistical methods were used to predetermine sample size. Hypoxia marker gene induction. To verify further induction of the hypoxia response program, hypoxia marker gene expression was verified. We analysed mRNA levels of genes encoding the E1B 19K/Bcl-2-binding protein Nip3 (BNIP3) and fructose-bisphosphate aldolase (ALDOA), 2 established hypoxia marker genes 33 . Reverse transcriptase-quantitative PCR (RT-qPCR) was performed as described for the TET mRNA concentration assays, and differential expression was calculated using the ΔΔ C t method 34 . We ruled out transcriptional upregulation as the cause of the increase in HIF1α protein concentrations by assessing HIF1A mRNA expression in parallel. mRNA concentrations were expressed relative to normoxic controls (21% O 2 ). Differences in mRNA concentration were assessed using a Student's t-test on 5 or more independent replicates grown on different days. Western blotting for Hif1α, Tet1, Tet2 and Tet3. To assess Hif1α protein stabilization, proteins were extracted from cultured cells as follows: cells were placed on ice, and washed twice with ice-cold PBS. Proteins were extracted with extraction buffer (50 mM Tris HCl, 150 mM NaCl, 1% Triton X-100, 0.5% sodium deoxycholate and 0.1% SDS) with 1× protease inhibitor cocktail. Protein concentrations were determined using a bicinchoninic acid protein assay (BCA, Thermo Scientific) following the manufacture's protocol. An estimated 60 μg protein was loaded per well on a NuPAGE Novex 3-8% Tris-Acetate Protein gel (Life Technologies), separated by electrophoresis and blotted on polyvinylidene fluoride membranes. Membranes were activated with methanol, washed and incubated with antibodies targeting β-actin (4967, Cell Signaling), Tet1 (09-872, Millipore) and Tet3 (61395, Active Motif), at 1:1,000 dilution, targeting Tet2 (124297, Abcam) at 1:250 dilution, and targeting Hif1α (C-Term) (Cayman Chemical Item 10006421) at 1:3,000 dilution. Secondary antibodies and detection were according to routine laboratory practices. Western blotting was performed on 6 independent replicates grown on different days. Analysis of HIF1β target genes using ChIP-seq. To confirm that hypoxiaassociated differential expression of TET genes is induced by the HIF pathway, we performed HIF1β ChIP-seq. Because HIF1β is the obligate binding partner of all three HIFα proteins stabilized and activated upon hypoxia 35 , HIF1β ChIP-seq reveals all direct HIF-target genes. Chromatin immunoprecipitation. Approximately 25 × 10 6 -30 × 10 6 cells were incubated in hypoxic conditions for 16 h. Cultured cells were subsequently immediately fixed by adding 1% formaldehyde (16% formaldehyde (w/v), Methanol-free, Thermo Scientific) directly to the medium and incubating for 8 min. Fixed cells were incubated with 150 μM of glycine for 5 min to revert cross-links, washed twice with ice-cold PBS 0.5% Triton X-100, scraped and collected by centrifugation (1,000g for 5 min at 4°C). The pellet was re-suspended in 1,400 μl of RIPA buffer (50 mM Tris-HCl pH 8, 150 mM NaCl, 2 mM EDTA pH 8, 1% Triton X-100, 0.5% sodium deoxycholate, 1% SDS, 1% protease inhibitors) and transferred to a new Eppendorf tube. The lysate was homogenized by passing through an insulin syringe, and incubated on ice for 10 min. The chromatin was sonicated for 3 min by using a Branson 250 Digital Sonifier with 0.7 s 'On' and 1.3 s 'Off ' pulses at 40% power amplitude, yielding a size of 100 to 500 bp. The sample was kept ice cold at all times during the sonication. The samples were centrifuged (10 min at 16,000g at 4 °C) and the supernatant were transferred in a new Eppendorf tube. The protein concentration was assessed using a BCA assay. Fifty microlitres of shared chromatin was used as 'input' and 1.4 μg of primary ARNT/HIF-1β monoclonal antibody (NB100-124, Novus) per 1 mg of protein was added to the remainder of the chromatin, and incubated overnight at 4 °C in a rotator. Pierce Protein A/G Magnetic Beads (Life Technologies) were added to the samples in a volume four times the volume of the primary antibody and incubated at 4 °C for at least 5 h. A/G Magnetic Beads were collected and the samples were washed five times with the washing buffer (50 mM Tris-HCl, 200 mM LiCl, 2 mM EDTA, pH 8, 1% Triton, 0.5% sodium deoxycholate, 0.1% SDS, 1% protease inhibitors), and twice with a 10 mM Tris, 1 mM EDTA (TE) buffer. The A/G magnetic beads were re-suspended Article reSeArcH in 50 μl of TE buffer, and 1.5 μl of RNase A (200 units, NEB) were added to the A/G beads samples and to the input, incubated for 10 min at 37 °C. After addition of 1.5 μl of proteinase K (200 U) and overnight incubation at 65 °C, the DNA was purified using 1.8× volume of Agencourt AMPure XP (Beckman Coulter) according to the manufactory instructions, and then eluted in 15 μl of TE buffer. The input DNA was quantified on NanoDrop. ChIP-seq, mapping and analysis. In total, 5 μg of input and all of the immunoprecipitated DNA was converted into sequencing libraries using the NEBNext DNA library prep master mix set. A single end of these libraries was sequenced for 50 bases on a HiSeq 2000, mapped using Bowtie and extended for the average insert size (250 bases). ChIP peaks were called by model-based analysis for ChIP-Seq 36 , with standard settings and using a sequenced input sample as baseline. Patient-derived xenografted tumours. To assess whether tumour-associated hypoxia reduces 5hmC levels in vivo, redundant material from two endometrial tumours and a breast tumour, removed during surgery, was grafted in the interscapular region of nude mice. Informed consent was obtained from the patient, following the ethical approval of the local ethical committee. All animal experiments were approved by the local ethical committee (P098/2014). Each tumour was allowed to grow to 1 cm 3 , after which it was collected. 10% of this tumour was re-implanted in a nude mouse, and the tumour was propagated for three generations until it was used for this experiment. To mark hypoxic areas, mice were injected with pimonidazole (60 mg kg −1 , Hypoxyprobe) i.p. 1 h before killing. Immunofluorescence staining and analysis. Tumours were collected, fixed in formaldehyde and embedded in paraffin using standard procedures. Paraffin was removed and slides were rehydrated in two xylene baths (5 min), followed by five 3-min ethanol baths at decreasing concentrations (100%, 96%, 70%, 50% and water) and a 3-min TBS (50 mM Tris, 150 mM NaCl, pH 7.6) bath.
The following antibodies were used for immunofluorescence staining: primary antibodies were FITC-conjugated mouse anti-pimonidazole (HP2-100, Hydroxyprobe), rabbit anti-5hmC (39791, Active Motif), rat anti-polyoma middle T (AB15085, Abcam), rat anti-CD31 (557355, BD Biosciences), rat anti-CD45 (553076, BD Biosciences), rabbit anti-Ki67 (AB15580, Abcam) and mouse anti-pan cytokeratin (C2562, Sigma). Secondary antibodies were Alexa Fluor 405-conjugated goat anti-rabbit (A31556, Thermo Fisher), Alexa Fluor 647 conjugated goat anti-rat (A-21247, Life Technologies), peroxidase-conjugated goat anti-FITC (PA1-26804, Pierce), biotinylated goat anti-rat (A10517, Thermo Fisher) and biotinylated goat anti-rabbit (E043201, Dako). Signal amplification was performed using the TSA Fluorescein System (NEL701A001KT, Perkin Elmer) or the TSA Cyanine 5 System (NEL705A001KT, Perkin Elmer).
Different protocols were implemented depending on the epitopes of interest. Staining for the following epitopes was combined: CD45, 5hmC, pimonidazole and DNA; PyMT, 5hmC, pimonidazole and DNA; Ki67, pimonidazole and DNA; CD31 and pimonidazole; and pan-cytokeratin, 5hmC, pimonidazole and DNA.
Antigen retrieval for CD31, CD45 and pan-cytokeratin was done by a 7-min trypsin digestion, for pimonidazole and Ki67 using AgR at 100 °C for 20 min, followed by cooling for 20 min. Slides were washed in TBS for 5 min, permeabilized in 0.5% Triton X-100 in PBS for 20 min. For 5hmC antigen retrieval, slides were denatured in 2 M HCl for 10 min; HCl was neutralized for 2 min in borax, 1% in PBS pH 8.5, and washed twice for 5 min in PBS.
For all slides, endogenous peroxidase activity was quenched using H 2 O 2 (0.3% in methanol), followed by three 5-min washes in TBS. Slides were blocked using pre-immune goat serum (X0907, Dako; 20% in TNB; TSA Biotin System kit, Perkin Elmer). Binding of primary antibodies (anti-5hmC, anti-CD45, anti-CD31 and anti-pan cytokeratin or FITC-conjugated anti-pimonidazole; all 1:100 in TNB) was allowed to proceed overnight. Slides were washed 3 times in TNT (0.5% Triton-X100 in TBS) for 5 min, after which the following secondary antibodies (all 1:100 in TNB with 10% pre-immune sheep serum) were allowed to bind for 45 min: sheep-anti-FITC-PO (for pimonidazole), goat anti-rabbit-Alexa Fluor 405 (for 5hmC), goat anti-rat-Alexa Fluor 647 (for CD45), and biotinylated goat antimouse (for pan-cytokeratin). Slides were washed three times for 5 min in TNT, after which signal amplification was performed for 8 min using Fluorescein Tyramide (1:50 in amplification diluent).
Slides stained for pimonidazole that required co-staining for Ki67 or PyMT, or slides stained for pan-cytokeratin that required co-staining for pimonidazole were subjected to a second indirect staining for the latter epitopes. After 5 min of TNT and 5 min of TBS, slides were quenched again for peroxidase activity using H 2 O 2 and blocked using pre-immune goat serum, prior to a second overnight round of primary antibody binding (anti-Ki67, FITC-anti-pimonidazole or anti-PyMT, all 1/100). The next day, three 5-min washes with TNT were followed by a 1-h incubation with a biotinylated goat anti-rabbit antibody (for Ki67) or goat anti-rat (for PyMT), another three 5-min washes with TNT, a 30-min incubation with peroxidase conjugated to streptavidin (for Ki67 and PyMT) or to anti-FITC (for pimonidazole), another three 5-min washes with TNT and signal amplification for 8 min using, for pimonidazole, Fluorescein Tyramide and for others Cyanine 5 Tyramide (1:50 in amplification diluent). Slides were then stained with propidium iodide with RNase (550825; BD biosciences) for 15 min, washed for 5 min in PBS and mounted with Prolong Gold (Life Technologies).
Slides were imaged on a Nikon A1R Eclipse Ti confocal microscope. Three to five sections per slide were imaged, and processed using Image J. Nuclei were identified using the propidium iodide signal and nuclear signal intensities for Fluorescein and Cy3 (pimonidazole and 5hmC) measured. Analyses were exclusively performed on slide regions showing a regular density and shape of nuclei, in order to avoid inclusion of acellular or necrotic areas. The pimonidazole signal will also not stain necrotic/acellular areas 37 , and was used to stratify viable cell nuclei into normoxic (pimonidazole negative) and hypoxic (pimonidazole positive) regions. The 5hmC signals in each population were compared using ANOVA. PyMT-negative and CD45-positive cells were counted directly. The fraction of pimonidazole and CD31-positive areas was directly quantified using ImageJ across ten images per slide. Metabolite and protein extraction. For metabolite extractions, 12-well cell culture dishes were placed on ice and washed twice with ice-cold 0.9% NaCl, after which 500 μl of ice-cold 80% methanol was added to each well. Cells were scraped and 500 μl was transferred to a vial on ice. Wells were washed with 500 μl 80% methanol, which was combined with the initial cell extracts. The insoluble fraction was pelleted at 4 °C by a 10-min 21,000g centrifugation. The pellet (containing the proteins) was dried, dissolved in 0.2 N NaOH at 96 °C for 10 min and quantified using a bicinchoninic acid protein assay (BCA, Pierce), whereas the supernatant fraction was processed for metabolite profiling. Derivation and measurement of metabolites. The supernatant fraction containing the metabolites was transferred to a new vial and dried in a Speedvac. The dried supernatant fraction was dissolved in 45 μl of 2% methoxyamine hydrochloride in pyridine and held for 90 min at 37 °C in a horizontal shaker, followed by derivatization through the addition of 60 μl of N-(tert-butyldimethylsilyl)n-methyl-trifluoroacetamide with 1% tert-butyldimethylchlorosilane and a 60-min incubation at 60 °C. Samples were subsequently centrifuged for 5 min at 21,000g and 85 μl was transferred to a new vial and analysed using a gas-chromatography based mass spectrometer (triple quadrupole, Agilent) operated in Multiple Reaction Monitoring (MRM) mode. Analysis of metabolite concentrations. For each sample, metabolite measurements were normalized per sample to the corresponding protein concentration estimates and expressed relative to control-treated samples. Four technical replicates were run for each sample, and the experiment was repeated 4 times using independent samples (n = 16). Differences in metabolite concentration were assessed using a two-tailed paired Student's t-test or using analysis of variance with post-hoc Tukey HSD when repeated measures were compared. ROS measurement using 2',7'-dichlorodihydrofluorescein diacetate. MCF7 cells were cultured in 24-well plates and exposed to 21% (control) or 0.5% O 2 (hypoxia) for 24 h. DMEM used for staining was pre-equilibrated to the required O 2 tension, and all steps performed at 21% (control) or 0.5% O 2 (hypoxia) using a glove box. The cells were washed twice with 500 μl DMEM, and incubated for 30 min in 2',7'-dichlorodihydrofluorescein diacetate (DCF-DA; 10 μM) in 500 μl DMEM, keeping 2 wells unstained by DMEM without DCF-DA. Cells were treated with the indicated concentrations of H 2 O 2 in DMEM for 30 min at 37 °C, and fixed by adding 33.3 μl of 16% methanol-free paraformaldehyde (Thermo Fisher) for 8 min at room temperature. The fixative was quenched using glycine (150 μM), cells were washed twice in ice-cold PBS, scraped to detach them and transfer them to pre-cooled FACS tubes over cell strainers. Cells were kept on ice until they were analysed by flow cytometry using a FACSVerse (BD Biosciences). Nuclear ROS measurement using nuclear peroxy emerald 1. MCF7 cells were seeded on 12-well glass-bottom plates and after 24 h exposed to 21% (control) or 0.5% O 2 (hypoxia) for 24 h. PBS used for subsequent staining was pre-equilibrated to the required O 2 tension, and all washing, treatment and staining steps were performed at the appropriate O 2 tension (21% or 0.5%) using a glove box. Cells were loaded with nuclear peroxy emerald 1 (NucPE1; 5 μM) 38, 39 and Hoechst 33342 (10 μg ml −1 ) in PBS for 15 min at 37 °C. After washing three times in PBS, control cells were incubated with H 2 O 2 (0.5 mM in PBS) as a positive control, or with water (control and hypoxia cells) in PBS at 37 °C for 20 min. Cells were washed three times in PBS, placed on ice and immediately imaged by confocal microscopy. The nuclear NucPE1 signal was measured, and averaged across >100 nuclei per replicate using ImageJ. This experiment was repeated 5 times on different days, and signals compared using a t-test. Cell growth measurement using Sulforhodamine B. 5,000 cells/well were seeded in three 96-well plates. After 48 h, one plate was fixed using trichloroacetic acid (3.3% w/v) for 1 h at 4 °C, one plate incubated for 24 h at 37 °C under hypoxic and one under control conditions (0.5% and 21% O 2 , respectively). The latter 2 plates were subsequently also fixed using trichloroacetic acid (3.3% wt/vol) for 1 h at 4 °C, and all 3 plates were next analysed using the In vitro Toxicology Assay Kit, Sulforhodamine B-based (Sigma) as per the manufacturer's instructions. Growth inhibition was calculated as described 40 . siRNA transfection. siRNA ON-TARGETplus SMART pools (Thermo) were diluted in Optimem I reduced serum medium using Lipofectamine RNAiMAX (Life technologies) to reverse-transfect MCF7 cells in 10-cm dishes (for DNA) or 6-well plates (for RNA). Cells were transfected 72 h before RNA and DNA extraction as described. Hydroxylation assay using nuclear extracts. MCF7 cells were cultured for 24 h under control or hypoxic conditions (21% or 0.5% O 2 , respectively), chilled on ice and processed for extraction of nuclear proteins using the NE-PER Nuclear and Cytoplasmic Extraction Kit (Thermo Scientific). The activity of control and hypoxic extracts was assessed in parallel using the Colorimetric Epigenase 5mC-Hydroxylase TET Activity/Inhibition Assay Kit (Epigentek) according to manufacturer's instructions. Reactions were allowed to proceed for one hour, after which washing and detection of 5hmC were done according to manufacturer's instructions. Differences between hypoxia and control were analysed using ANOVA, for 5 independent experiments. DNA hydroxymethylation assay using purified Tet enzyme. The genomic DNA used in this assay was extracted from Tet triple-knockout ES cells (G. -L. Xu), and it therefore was devoid of 5hmC 41 . To enable efficient denaturation, it was digested using MseI before the assay and purified using solid phase reversible immobilisation paramagnetic beads (Agencourt AMPure XP, Beckman Coulter). The assays were performed in Whitley H35 Hypoxystations (don Whitley Scientific) at 37 °C, 5% CO 2 , N 2 , with the following oxygen tensions: 0.1%, 0.3%, 0.5%, 1%, 2.5%, 5%, 10% and 21%. Hypoxystations were calibrated less than 1 month before all experiments. Optimized assay components were as follows: 1.0 μg μl −1 bovine serum albumin (New England Biolabs), 50 mM Tris (pH 7.8), 100 μM dithiothreitol (Life Technologies), 2 ng μl −1 digested gDNA, 250 μM α-ketoglutarate, 830 μM ascorbate, 200 μM FeSO 4 and 45 ng μl −1 Tet1 enzyme (Wisegene). The major assay components (H 2 O, BSA and Tris) used for all samples were allowed to pre-equilibrate at 0.1% O 2 for 1 h. These and the remaining assay buffer components (<100 μl) were then pre-equilibrated at the desired oxygen tension for 15 min, and mixed before addition of Tet1 enzyme in a total reaction volume of 25 μl. Reactions were allowed to proceed for 3 min, longer incubations showed a decrease in activity. Reactions were stopped with 80 mM EDTA and stored at −80 °C. To measure the resulting 5hmC content of the DNA, reactions were diluted to 100 μl, denatured for 10 min at 98 °C and analysed in duplicate using the Global 5-hmC Quantification Kit (Active Motif) following manufacturer's instructions. Michaelis-Menten and Lineweaver-Burk plots and the resulting K M values were estimated using R.
Hypoxia-induced changes in genomic distribution of 5(h)mC in MCF7 cells: DIP-seq.
To assess where in the genome the levels of 5mC and 5hmC were altered, we performed DNA immunoprecipitations coupled to high-throughput sequencing (DIP-seq). MCF7 cells were selected for these experiments as they were a cancer cell line with high levels of 5hmC and expression of TET genes under control conditions, and a cell growth that is unaffected by hypoxia. This enabled us to study the effects of hypoxia on TET activity in a cell line that shows high endogenous activity, but that is isolated from hypoxia-induced changes in cell proliferation. MCF7 cell culture and DNA extractions were as described for LC-MS analyses. Library preparations and DNA immunoprecipitations were performed as described 42 , using established antibodies targeting 5mC (clone 33D3, Eurogentec,) and 5hmC (Active Motif catalogue number 39791). For 5hmC-DIP-seq, paired barcoded libraries prepared from DNA of hypoxic and control samples were mixed before capture, to enable a direct comparison of 5hmC-DIP-seq signal to the input. A single end of these libraries was sequenced for 50 bases on a HiSeq 2000, mapped using Bowtie and extended for the average insert size (150 bases). Mapping statistics are summarized in Supplementary Information Table 11 .
For analysis of sequencing data, MACS peak calling, read depth quantification and annotation with genomic features as annotated in EnsEMBL build 77 was performed using SeqMonk. Differential (hydroxy-)methylation was quantified by EdgeR 43 , using either 3 or 5 independent pairs of control and hypoxic samples (for 5hmC-DIP-seq and 5mC-DIP-seq, respectively). These cells were cultured and exposed to hypoxia (0.5% O 2 ) or control conditions (21% O 2 ) on different days. Results were reported for 5hmC peak areas that exhibited a change significant at a P < 0.05 and 5% FDR. Target enrichment BS-seq using SeqCapEpi. To confirm enrichment of 5mC at gene promoters using an independent method, DNA libraries were prepared using methylated adapters and the NEBNext DNA library prep master mix set following manufacturer recommendations. Libraries were bisulfite-converted using the Imprint DNA modification kit (Sigma) as recommended, and PCR amplified for 12 cycles using barcoded primers (NEB) and the KAPA HiFi HS Uracil+ ready mix (Sopachem) according to manufacturer's instructions. Fragments were selected from these libraries using the SeqCapEpi CpGiant Enrichment Kit (Roche) following the manufacturer's instructions, sequenced from both ends for 100 bases on a HiSeq 2000.
For analysing these sequences, sequencing reads were trimmed for adapters using TrimGalore and mapped on a bisulfite-converted human genome (GRCh37) using BisMark. The number of methylated and un-methylated cytosines in captured regions was quantified using Seqmonk for each experiment. Differential methylation of regions of interest was assessed by Fisher's exact test and for 5 independent replicates grown on different days. t-scores were averaged following Fisher's method. Mapping statistics are summarized in Supplementary Table 11 . RNA-seq. To assess the effect of the increased 5mC occupancy at gene promoters on their expression, RNA-seq was performed. Briefly, total RNA was extracted using TRIzol (Invitrogen), and remaining DNA contaminants in 17-20 μg of RNA was removed using Turbo DNase (Ambion) according to the manufacturer's instruction. RNA was repurified using RNeasy Mini Kit (Qiagen). Ribosomal RNA present was depleted from 5 μg of total RNA using the RiboMinus Eukaryote System (Life technologies). cDNA synthesis was performed using SuperScript III Reverse Transcriptase kit (Invitrogen). 3 μg of Random Primers (Invitrogen), 8 μl of 5× First-Strand Buffer and 10 μl of RNA mix was incubated at 94 °C for 3 min and then at 4 °C for 1 min. 2 μl of 10 mM dNTP Mix (Invitrogen), 4 μl of 0.1 M DTT, 2 μl of SUPERase In RNase Inhibitor 20U μl −1 (Ambion), 2 μl of SuperScript III RT (200 U μl −1 ) and 8 μl of Actinomycin D (1 μg μl −1 ) were then added and the mix was incubated for 5 min at 25 °C, 60 min at 50 °C and 15 min at 70 °C to heat-inactivate the reaction. The cDNA was purified by using 80 μl (2× volume) of Agencourt AMPure XP and eluted in 50 μl of the following mix: 5 μl of 10× NEBuffer 2, 1.5 μl of 10 mM dNTP mix (10 mM dATP, dCTP, dGTP, dUTP, Sigma), 0.1 μl of RNaseH (10 Uμl −1 , Ambion), 2.5 μl of DNA Polymerase I Klenov (10 U μl −1 , NEB) and the remaining volume of water. The eluted cDNA was incubated for 30 min at 16 °C, purified by Agencourt AMPure XP and eluted in 30 μl of dA-Tailing mix (2 μl of Klenow Fragment, 3 μl of 10× NEBNext dA-Tailing Reaction Buffer and 25 μl of water). After 30 min incubation at 37 °C, the DNA was purified by Agencourt AMPure XP, eluted in TE buffer and quantified on NanoDrop. Subsequent library preparation was performed using the DNA library prep master mix set and sequencing was performed as described for ChIP-seq. Expression levels (reads per million) of genes displaying significant increases in methylation at their gene promoter, as determined using SeqCapEpi, was compared between control and hypoxic samples using a t-test. Mapping statistics are summarized in Supplementary Table 11 . TCGA samples and data analysis. From the TCGA pan-cancer analysis, we selected all solid tumour types for which >100 tumours were available with both gene expression data (RNA-seq) and DNA methylation data (Illumina Infinium HumanMethylation450 BeadChip). These were 408 bladder carcinomas, 691 breast carcinomas, 243 colorectal adenocarcinomas, 520 head and neck squamous cell carcinomas, 290 kidney renal cell carcinomas, 430 lung adenocarcinomas, 371 lung squamous cell carcinomas, and 188 uterine carcinomas, representing in total 3,141 unique patients. Corresponding RNA-seq read counts as well as DNA methylation data from Infinium HumanMethylation450 BeadChip arrays were downloaded from the TCGA server. Breast tumour subtypes were annotated for 208 tumours and, for the remaining tumours, imputed by unsupervised hierarchical clustering of genes in the PAM50 gene expression signature 44 . Other clinical and histological variables were available for >95% of tumours, and missing values were encoded as not available. Gene mutation data was available for 129 bladder carcinomas, 646 breast carcinomas, 200 colorectal adenocarcinomas, 306 head and neck squamous cell carcinomas, 241 kidney renal cell carcinomas, 182 lung adenocarcinomas, 74 lung squamous cell carcinomas, and 3 uterine carcinomas. Stratification of tumours for hypoxia and proliferation. To identify which of these tumour samples were hypoxic or normoxic, we performed unsupervised hierarchical clustering based a modification (Ward.D of the clusth function in R's stats package) of the Ward error sum of squares hierarchical clustering method 45 , on normalized log 10 -transformed RNA-seq read counts for 14 genes that make up the hypoxia metagene signature (ALDOA, MIF, TUBB6, P4HA1, SLC2A1, PGAM1, ENO1, LDHA, CDKN3, TPI1, NDRG1, VEGFA, ACOT7 and ADM) 25 . In each case the top 3 sub-clusters identified were annotated as normoxic, intermediate and hypoxic. To identify which of these tumour samples were high-or low-proliferative, we performed unsupervised hierarchical clustering based a modification (Ward.D of the clusth function in R's stats package) of the Ward error sum of squares hierarchical clustering method 45 , and this for all genes annotated to an established tumour proliferation signature (MKI67, NDC80, NUF2, PTTG1, RRM2, BIRC5, CCNB1, CEP55, UBE2C, CDC20 and TYMS) 46 . Tumours in the top 2 sub-clusters identified were labelled as high-or low-proliferative. Analysis of the top 1000 CpGs most hypermethylated versus normal tissue. To identify tumour-associated hypermethylation events, we compared 450k methylation data from tumours and normal tissues. All available DNA methylation data from normal tissue (matched or unmatched to tumour samples, on average Article reSeArcH 59 per tumour type, representing 472 in total, range = 21-160) were downloaded. For each of the 8 tumour types investigated, we selected the top 1,000 CpGs that showed the highest average tumour-associated increases in DNA methylation. Per tumour type, unsupervised hierarchical clustering based on a modification of the Ward error sum of squares hierarchical clustering method (Ward.D of the clusth function in R's stats package) 45 annotated the first 3 clusters identified as having low, intermediate and high hypermethylation. Cluster co-membership for methylation and hypoxia metagene expression were analysed using the Cochran-Armitage test for trend. Analyses using the top 100, 500, 5,000 or 10,000 CpGs yielded near identical results (not shown). Analysis of hypermethylation events. We next applied a method to identify those CpGs that exhibit exceptional increases in hypermethylation but that are hypermethylated only in a subset of all tumours. Such rare events are typically found in cancer, where hypermethylation inactivates a gene in only a subset of tumours. Hypermethylation of individual CpGs at gene promoters (that is, on average 3.7 CpGs per promoter are represented on the 450K array) in individual tumours was assessed as follows: To achieve a normal distribution, all β-values were transformed to M-values 47 using M = log 2 (β/(1 − β)). For each tumour type, the mean μ and standard deviation σ of the M value across all control (normoxic) tumours was next calculated, irrespective of mutational status, for each CpG, and used to assign Z-values to each CpG in each tumour using Z = (M − μ)/σ. These Z-values describe the deviation in normal methylation variation for that probe. To identify CpGs that display an extreme deviation, we selected those for which the Z-value exceeded 5.6 (that is, μ + (5.6 × σ), corresponding to a Bonferroni-adjusted P value of 0.01); they were considered as hypermethylation events in that particular tumour. This analysis was preferred over Wilcoxon-based models that assess differences in the average methylation level between subgroups, as the latter do not enable the identification or quantification of the rarer hypermethylation events in individual promoters or CpGs.
To identify genes with frequently hypermethylated CpGs in their promoter, the number of hypermethylation events in that promoter was counted in all tumours, and contrasted to the expected number of hypermethylation events in that promoter (that is, the general hypermethylation frequency multiplied by the number of CpGs assessed in that promoter multiplied by the number of tumours) using Fisher's exact test. Genes with an associated Bonferroni-adjusted P value below 0.01 were retained and considered as frequently hypermethylated in that tumour type.
To assess what fraction of these hypermethylation events are hypoxia-related, we assumed that the fraction of events detected under normoxia was hypoxiaunrelated, and that all excess events detected in intermediate and hypoxic tumours were hypoxia-related. For example, in 691 breast carcinomas, 0.25% of CpGs were hypermethylated in 251 normoxic tumours, 0.81% in 350 intermediate and 1.40% in 90 hypoxic tumours. So, 0.56% and 1.15% of hypermethylation events in respectively intermediate and hypoxic tumours were hypoxia-related. Taking into account the number of tumours, 0.25% of hypermethylation events (that is, (0.25% × 251 + 0.25% × 350 + 0.25% × 90)/691) are not hypoxia-related, and 0.43% are hypoxia related (that is, (0% × 251 + 0.56% × 350 + 1.15% × 90)/691). So, 63% of all hypermethylation events combined (that is, 0.43/(0.43 + 0.25)) are hypoxia related. To assess the contribution of hypoxia to hypermethylation relative to other covariates, partial R 2 values were calculated for the contribution of each covariate in a linear model, and compared to the total R 2 achieved by the model.
To identify genes with CpGs in their promoter that are more frequently hypermethylated in hypoxic than normoxic tumours, the number of hypermethylation events in that promoter was counted in all hypoxic tumours, and contrasted to the number found in normoxic tumours. Differences in frequencies were assessed using Fisher's exact test, and genes with a Bonferroni-adjusted P < 0.01 were retained and considered hypermethylated upon hypoxia. Enrichment of ontologies associated with these genes was assessed using Fisher's exact test as implemented in R's topGO package.
Analysis of the effect of hypermethylation events on the expression of associated genes.
To enable a direct comparison between the expression of different genes, we transformed gene expression values (reads per million) to their respective z-scores. To assess the impact of hypermethylation events on the expression of associated genes, we compared the expression z-scores of all frequently hypermethylation genes that contain one or more hypermethylation events in their promoter (on average each promoter contains 3.7 CpGs; if one of these is hypermethylated the associated gene is considered hypermethylated in that particular tumour), to the expression of all frequently hypermethylated genes that do not contain a hypermethylation event. The effect of hypermethylation on gene expression was plotted for the 8 main tumour types stratified into normoxic, intermediately hypoxic and hypoxic tumours, and for glioblastomas was stratified into normoxic, intermediately hypoxic, hypoxic and IDH-mutant tumours (n = 4). The difference in expression z-scores between genes not carrying and carrying a hypermethylation event in their promoter was assessed using a t-test.
Analysis of the effect of frequent mutations on the occurrence of hypermethylation events. To assess the impact of somatic mutations on hypoxia-associated hypermethylation frequencies, we analysed the top 20 genes described to be most frequently mutated in the pan-cancer analysis 24 , and supplemented this list with genes known to cause hypermethylation upon mutation (that is, IDH1, IDH2, SDHA, FH, TET1, TET2 and TET3). Mutations in IDH1 and IDH2 were retained if they respectively affected amino acid R132, and amino acids R140 or R172. Mutations in other genes were scored using Polyphen, and only mutations classified as probably damaging were retained. 7 mutations were found in lung tumours, 3 mutations in colorectal tumours, 8 mutations in breast tumours and 6 mutations (all IDH1 R132 ) in glioblastomas. None of these mutations were enriched in hypoxic subsets. In multivariate analyses of variance, in each of the tumour types analysed, mutations in these genes were significantly associated with increased hypermethylation frequencies. Hypoxia was independently and significantly associated with the hypermethylation frequency.
Correlation between hypermethylation and expression of TET or DNMT enzymes. Gene expression values (reads per million) of DNMT and TET enzymes
were determined for each tumour using available RNA-seq data. The number of hypermethylation events at significantly hypermethylated genes in each tumour was determined as described above. Hypermethylation in each tumour was subsequently correlated to TET or DNMT gene expression in that tumour, correcting for hypoxia and proliferation status using ANOVA. 5mC and 5hmC profiling using 450k arrays for 24 lung tumours. Newly diagnosed and untreated non-small-cell lung cancer patients scheduled for curativeintent surgery were prospectively recruited. Included subjects had a smoking history of at least 15 pack-years. The study protocol was approved by the Ethics Committee of the University Hospital Gasthuisberg (Leuven, Belgium). All participants provided written informed consent. In the framework of a different project 48 , RNA-seq was performed on 39 tumours from these patients. Gene expression for these samples was clustered for their hypoxia metagene signature 25 . This yielded 2 clear clusters, containing 24 and 15 normoxic and hypoxic tumours, respectively. Twelve samples were randomly selected from each cluster, in order to perform 5hmC and 5mC profiling. Illumina Infinium HumanMethylation450 BeadChips. For TAB-ChIP, DNA was glycosylated and oxidized as described 49 , using the 5hmC TAB-Seq Kit (WiseGene). Subsequently, bisulfite conversion, DNA amplification and array hybridization were done following manufacturer's instructions. Analysis of TAB-ChIP and BS-ChIP. Data processing was largely as described 50 . In brief, intensity data files were read directly into R. Each sample was normalized using Subset-quantile within array normalization (SWAN) for Illumina Infinium HumanMethylation450 BeadChips 49 . Batch effects between chips and experiments were corrected using the runComBat function from the ChAMP bioconductor package 51 . For obtaining 5mC-specific beta values, TAB-ChIP generated normalized beta values were substracted from the standard 450K generated normalized beta values, exactly as described 50 . Mouse cancer models. All the experimental procedures were approved by the Institutional Animal Care and Research Advisory Committee of the KU Leuven. Hypoxia induction using sFlk1-overexpression. For sFlk1-overexpression studies, male Tg(MMTV-PyMT) FVB mice were intercrossed with wild-type FVB female mice. Female pups of the Tg(MMTV-PyMT) genotype were retained, and tumours allowed to develop for 9 weeks. Subsequently, 2.5 μg of plasmid (sFlk1-overexpressing or empty vector; randomly assigned within litter mates) per gram of mouse body weight was introduced in the bloodstream using hydrodynamic tail vein injections 52 . sFlk1 overexpression was monitored at 4 days after injection and at the day of killing (18 days after the injection), by eye bleeds followed by an ELISA assay for sFlk1 (R&D Systems) in blood plasma. At 12 weeks of age, mice were killed and mammary tumours collected were blinded for treatment. Hypoxia reduction using Phd2 haplodeficiency. For the Phd2 +/− experiments, male Tg(MMTV-PyMT) FVB mice were intercrossed with female Phd2 −/+ mice, yielding litters of which half have either a Tg(MMTV-PyMT) genotype or a Tg(MMTV-PyMT);Phd2 −/+ genotype. For the Phd2 WT/fl experiments, male Tg(MMTV-PyMT) FVB mice were intercrossed with female Tie2-Cre;Phd2 WT/fl mice as described 27 , yielding litters of which half have either a Tie2-cre;Tg(MMTV-PyMT);Phd2 WT/WT genotype or a Tie2-cre;Tg(MMTV-PyMT);Phd2 −/+ genotype. At 16 weeks of age, female mice were killed and mammary tumours collected. qPCR analysis of expression of Tets and marker genes. RNA was extracted from fresh-frozen tumours (stored at −8 °C) using TRIzol (Life Technologies), and converted to cDNA and quantified as described for the cell lines. TaqMan probes and primers (IDT or Life Technologies) are described under Supplementary Table 12 . TAB-seq of PyMT tumours. TAB-seq libraries were prepared as described, using the 5hmC TAB-Seq Kit (WiseGene). DNA was bisulfite-converted using the EZ DNA Methylation-Lightning Kit (Zymo Research) and sequenced as described for SeqCapEpi experiments. Reads were mapped to the mouse genome (build Mm9) and further data processing was as for SeqCapEpi experiments. DNA from 3 independent tumours was selected per condition. TET oxidation efficiency was required to exceed 99.5% as estimated using a fully CG-methylated plasmid spike-in, 5hmC protection by glycosylation was 65% as estimated using a fully hydroxymethylated plasmid spike-in, bisulfite conversion efficiencies were estimated to exceed 99.8% based on nonCG methylation (equal to percentage hypermethylated CpG). Mapping statistics are summarized in Supplementary Table 11 . Targeted deep BS-seq. As no mouse capture kit was available for targeted BS-seq, a specific ampliconBS was developed for a set of 15 tumour suppressor gene promoters and 5 oncogene promoters. More specifically, DNA was bisulfite-converted using the Imprint DNA modification kit and amplified using the MegaMix Gold 2× mastermix and validated primer pairs. Per sample, PCR products were mixed to equimolar concentrations, converted into sequencing libraries using the NEBNext DNA library prep master mix set and sequenced to a depth of ~500×. Mapping and quantification were done as described for SeqCapEpi. The average and variance of methylation level M values in normal mammary glands were used as baseline, and amplicons displaying over 3 standard deviations more methylation (FDR-adjusted P < 0.05) than this baseline were called as hypermethylated. At least 9 different tumours, each from different animals, were profiled per genotype or treatment, and differences in hypermethylation frequencies between sets of tumours were assessed using Mann-Whitney's U-test. Statistics. Data entry and analysis were performed in a blinded fashion. Statistical significance was calculated by two-tailed unpaired t-test (Excel) or analysis of variance (R) when repeated measures were compared. Data were tested for normality using the D'Agostino-Pearson omnibus test (for n > 8) or the Kolmogorov-Smirnov test (for n ≤ 8) and variation within each experimental group was assessed. Data are presented as mean ± s.e.m. DNA methylation and RNA-seq gene expression data distributions were transformed to a normal distribution by conversion to M values and log 2 transformation respectively. Sample sizes were chosen based on prior experience for in vitro and mouse experiments, or on sample and data availability for human tumour analyses. Other statistical methods (mostly related to specific sequencing experiments) are described together with the experimental details in other sections of the methods.
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Extended Data Figure 2 | Impact of hypoxia on TET expression. a, Changes in Tet1, Tet2 and Tet3 expression in mouse cell lines, at the protein level (top row, n = 6) and the mRNA level (bottom row, n = 5). Middle row: representative immunoblot images of Hif1a, Tet1, Tet2 and Tet3. α-Tubulin serves as loading control, and expression of the corresponding coding gene (Tuba1a) was used to normalize mRNA expression, enabling a direct comparison of relative protein and relative mRNA expression changes. For the same reason, mRNA expression was depicted relative to control conditions, in contrast to the absolute levels shown in Extended Data Fig. 1 . Changes in Tet mRNA and protein expression correlate strongly (Pearson's R = 0.855, P = 4 × 10 −4 ). For example, both 4T1 and N2A cells displayed increased Tet2 expression at the protein and mRNA level. Likewise, ES cells showed no pronounced changes at the protein or mRNA level. The overall expression of Tet enzymes was not altered in any of these cell lines. For gel source data, see Supplementary Fig. 1. b, Hif1β ChIP-seq at the promoters of TET1, TET2 and TET3 and at hypoxia markers genes (Bnip3 and Aldoa), with peaks or promoter regions highlighted using coloured boxes. Green and red boxes correspond to overexpression and no overexpression (specified in the figure panel) of the corresponding gene, respectively, as determined using TaqMan in Extended Data Fig. 1 . Scale: reads per million reads and per base pair. c, Left, TET2 expression in MCF7 cells transfected with control (white) or TET2-targeting (purple) siRNAs. Right, corresponding 5hmC levels as determined using LC-MS. d, 5hmC levels as determined by LC-MS, in wild-type (white) and Tet1-knockout (purple) ES cells grown under 21% (left) and 0.5% (right) O 2 tensions. Bars in c and d represent the mean ± s.e.m. of five replicate samples from cells derived from the same stock vial but grown on different days. *P < 0.05, **P < 0.01, ***P < 0.001 by paired t-tests (a, c, d) .
Extended Data Figure 6 | Functional annotation of genes more frequently hypermethylated in hypoxic tumours. a, Ontology terms enrichment analysis of genes that are more frequently hypermethylated at their gene promoters in hypoxic than normoxic tumours, for eight tumour types characterized in the TCGA pan-cancer effort. A representative set of terms is displayed, selected from terms enriched in most tumour types. P values as defined by the grey-scale insert. Enrichment calculated using topGO. b, Selected examples of hypermethylation frequencies in the promoter of key TSGs (PTEN, CDKN1C, ATM) more frequently hypermethylated in normoxic than hypoxic tumours. c, Hypermethylation frequency in the promoter of selected genes involved in the processes indicated. P < 0.05 for all genes (asterisks are not displayed). Bars in b and c represent the hypermethylation frequency ± s.e.m. P values in a by Fisher's exact test.
